Q-omics provides the consensus-scored HNRNPDLP2 profile across patient tissues and cancer cell-line models. HNRNPDLP2 expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, HNRNPDLP2 is differentially expressed in 2, with the highest sampling consensus in KICH. Additionally, HNRNPDLP2 RNA expression shows 9,094 significant protein co-abundance associations, with the highest sampling consensus in HNSC. Together, these results highlight LUAD, KICH, and HNSC as cancer lineages where HNRNPDLP2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HNRNPDLP2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HNRNPDLP2 survival associations across molecular data types. HNRNPDLP2 RNA expression shows survival associations in the most cancer types (16). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HNRNPDLP2 RNA expression–survival associations across cancer types. High HNRNPDLP2 expression shows unfavorable associations in PAAD, MESO, HNSC and STAD, but favorable associations in LUAD and LGG. The LUAD Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .009). Together, the overview and detailed table identify LUAD as the clearest survival context for HNRNPDLP2 RNA expression.
This table summarizes HNRNPDLP2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for HNRNPDLP2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HNRNPDLP2 shows lower tumor expression in KICH and BRCA. The KICH box plot shows higher HNRNPDLP2 RNA expression in normal versus tumor tissue (log2 FC = −0.040, t-test p = .010).
This table shows molecular features associated with HNRNPDLP2 in patient tissues and cancer cell lines. In patient samples, HNRNPDLP2 shows the broadest associations at the RNA and protein expression levels, with HNSC recurring as the lineage with the largest associated feature set.
